GO
Loading...

Enter multiple symbols separated by commas

Merck & Co Inc

More

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, with the Dow above 18,000 for the first time in April as investors looked ahead to the official start of earnings season.

  • April 10- AstraZeneca Plc's diabetes drug Onglyza may be associated with an increased rate of death, according to a preliminary review of data by the U.S. Food and Drug Administration. The FDA's report, posted on the agency's website on Friday, comes ahead of an April 14 meeting of an FDA advisory panel to discuss the drug's safety. The FDA said the causes of death...

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • Early movers: RDSA, TSLA, MRK, RAD & more Wednesday, 8 Apr 2015 | 8:02 AM ET
    Trader on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks closed higher, rebounding from initial losses on the disappointing jobs report as weak data renewed hopes of a rate hike delay.

  • Biotech wins $45 million grant for Ebola vaccine Monday, 6 Apr 2015 | 9:28 AM ET
    Dr. Joseph Kim, founder of Inovio Pharmaceuticals

    Today's vaccine debate will be outdated if Inovio succeeds in developing DNA vaccines. Imagine a single needle shot that can cure Ebola.

  • Stocks close moderately lower on mixed data Wednesday, 1 Apr 2015 | 4:00 PM ET
    A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed lower on Wednesday as investors weighed softness in economic data ahead of Friday's important jobs report.

  • FRANKFURT, April 1- Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said. Roche is vying with rivals such as Bristol-Myers Squibb, Merck& Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune...

  • An outbreak of Ebola killed close to 10,000 people across West Africa over the last year, with Liberia, Guinea and Sierra Leone being the worst affected. Private company Mapp Biopharmaceutical and Tekmira Pharmaceuticals Corp have shown that their Ebola drugs could cure non-human primates. The other companies that are currently testing potential...

  • Lightning Round: Stay far away from this Friday, 27 Mar 2015 | 7:09 PM ET
    Mad Money Lightning Round

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Traders work the floor of the New York Stock Exchange.

    U.S. stocks plunged, closing more than 1 percent lower as investors weighed the impact of the strong dollar on the economy and earnings.

  • Merck increases share buyback plan   Wednesday, 25 Mar 2015 | 10:18 AM ET
    Merck increases share buyback plan

    The New Jersey-based drug giant buys back $10 billion worth of its own shares. CNBC's Landon Dowdy reports.

  • Early movers: KRFT, TSLA, AXP, AZO, FB & more Wednesday, 25 Mar 2015 | 7:58 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • A trader works on the floor of the New York Stock Exchange.

    U.S. stocks closed lower as investors attempted to find clarity on the timing of a rate hike amid concerns of the dollar's impact on earnings.

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • FRANKFURT, March 20- Germany's Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources. Merck, which is also the world's largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich, putting it on track to become the...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks closed mixed on Thursday as investors weighed the Federal Reserve statement that indicated a rate hike would come gradually.

  • FDA panel to discuss Ebola vaccine development in May Wednesday, 18 Mar 2015 | 8:16 AM ET

    March 18- The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. Ebola has so far claimed about 10,000 lives in Sierra Leone, Liberia and Guinea. Other companies that are testing potential treatments for...

  • Cramer: These trends are wreaking havoc right now Tuesday, 17 Mar 2015 | 6:12 PM ET
    A trader works on the floor of the New York Stock Exchange.

    Jim Cramer is seeing tons of inconsistency in the market right now. He no longer is trusting the trends that have made fortunes before.

  • March 17- Esperion Therapeutics Inc said its experimental drug lowered LDL or "bad" cholesterol levels in patients who were already on statins, the current standard of care. Needham& Co analyst Chad Messer said he expects the drug to be adopted faster as an additional therapy to statins rather than replacing statins altogether. There are about 35 million...